Cepheid Gets CE Mark for Drug-Resistant Bacteria Dx; Partners with Pharma for US Development | GenomeWeb

This article has been updated from a previous version to include information about Cepheid's pharmaceutical partnerships around the Xpert Carba-R assay.

NEW YORK (GenomeWeb) — Cepheid this week announced the European release of a new on-demand molecular diagnostic designed to test for multi-drug resistant pathogens, and said that it is collaborating with three US pharmaceutical partners to further develop the assay to help physicians prescribe the most beneficial antibiotics for patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.